NR1H4 and metabolic dysfunction-associated steatohepatitis: In addition, numerous FXR modulators have been discovered and their efficacy has been evaluated for the treatment of FXR-mediated liver diseases, such as PBC, NASH, biliary atresia, and APAP-induced liver failure.